5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.68▲ | 3.64▲ | 3.62▲ | 3.31▲ | 3.20▲ |
MA10 | 3.66▲ | 3.61▲ | 3.55▲ | 3.19▲ | 3.13▲ |
MA20 | 3.65▲ | 3.51▲ | 3.36▲ | 3.06▲ | 2.96▲ |
MA50 | 3.60▲ | 3.31▲ | 3.23▲ | 3.01▲ | 6.90▼ |
MA100 | 3.55▲ | 3.22▲ | 3.13▲ | 3.04▲ | 6.22▼ |
MA200 | 3.36▲ | 3.11▲ | 3.05▲ | 7.03▼ | 8.94▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.004▲ | 0.037▲ | 0.057▲ | 0.293▲ |
RSI | 77.132▲ | 69.113▲ | 69.171▲ | 71.914▲ | 44.292▼ |
STOCH | 76.174 | 49.920 | 61.456 | 66.070 | 66.777 |
WILL %R | -5.263▲ | -33.613 | -24.691▲ | -21.569▲ | -11.957▲ |
CCI | 192.107▲ | 65.231 | 83.333 | 338.397▲ | 191.565▲ |
Wednesday, January 06, 2021 06:18 AM
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...
|
Wednesday, January 06, 2021 05:00 AM
AKBA ), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia ...
|
Tuesday, January 05, 2021 01:31 PM
CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/01/21 | 3.48 | 3.93 | 3.46 | 3.71 | 11,856,011 |
22/01/21 | 3.15 | 3.395 | 3.10 | 3.36 | 6,538,800 |
21/01/21 | 3.22 | 3.235 | 3.11 | 3.15 | 6,312,635 |
20/01/21 | 3.19 | 3.29 | 3.10 | 3.17 | 9,843,100 |
19/01/21 | 3.117 | 3.22 | 3.04 | 3.14 | 6,008,100 |
15/01/21 | 3.14 | 3.16 | 3.04 | 3.05 | 4,209,600 |
14/01/21 | 3.131 | 3.20 | 3.095 | 3.17 | 5,245,100 |
13/01/21 | 3.07 | 3.25 | 2.97 | 3.11 | 16,802,200 |
12/01/21 | 3.07 | 3.10 | 3.00 | 3.05 | 3,948,200 |
11/01/21 | 3.08 | 3.15 | 3.01 | 3.04 | 3,889,528 |
|
|
||||
|
|
||||
|
|